Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN decreased its stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 7.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,880 shares of the company’s stock after selling 7,352 shares during the period. Wells Fargo & Company MN owned approximately 0.14% of Pliant Therapeutics worth $1,131,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new position in Pliant Therapeutics during the 4th quarter valued at about $33,000. KLP Kapitalforvaltning AS acquired a new position in Pliant Therapeutics during the 4th quarter valued at about $108,000. Atria Investments Inc increased its stake in Pliant Therapeutics by 18.1% during the 4th quarter. Atria Investments Inc now owns 11,821 shares of the company’s stock valued at $156,000 after buying an additional 1,812 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Pliant Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,903 shares of the company’s stock valued at $170,000 after buying an additional 1,209 shares during the period. Finally, SG Americas Securities LLC increased its stake in Pliant Therapeutics by 27.2% during the 4th quarter. SG Americas Securities LLC now owns 30,729 shares of the company’s stock valued at $405,000 after buying an additional 6,579 shares during the period. Institutional investors and hedge funds own 97.30% of the company’s stock.

Pliant Therapeutics Price Performance

Shares of NASDAQ:PLRX opened at $1.47 on Tuesday. The company’s fifty day moving average is $1.70 and its two-hundred day moving average is $8.62. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. Pliant Therapeutics, Inc. has a 12-month low of $1.10 and a 12-month high of $16.52. The company has a market cap of $90.24 million, a P/E ratio of -0.44 and a beta of 1.46.

Pliant Therapeutics (NASDAQ:PLRX) last announced its earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.17. Equities analysts expect that Pliant Therapeutics, Inc. will post -3.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on PLRX. Needham & Company LLC restated a “hold” rating and set a $10.00 price objective on shares of Pliant Therapeutics in a research report on Tuesday, March 4th. Canaccord Genuity Group restated a “hold” rating and set a $4.00 price objective (down previously from $43.00) on shares of Pliant Therapeutics in a research report on Monday, February 10th. Leerink Partnrs lowered shares of Pliant Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. lowered shares of Pliant Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, February 10th. Finally, Royal Bank of Canada reduced their price objective on shares of Pliant Therapeutics from $4.00 to $3.00 and set a “sector perform” rating for the company in a research report on Tuesday, March 4th. Twelve investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Pliant Therapeutics has a consensus rating of “Hold” and a consensus target price of $13.31.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.